# Digital Health Sector

Canonical URL: https://biopharmsignal.com/sector/digital-health

Digital Health is a company sector tag on BioPharmSignal. This page groups public biotech and healthcare companies associated with Digital Health, making it easier to scan related businesses, compare peers, and follow companies exposed to the same modality, disease area, or development theme.

Companies currently grouped under Digital Health: 62

## Recent Sector News

- 2026-07-16 13:00 EST — INBX — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-07-14 11:00 EST — BEAT — [HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device](https://biopharmsignal.com/news/BEAT/heartbeam-awarded-new-u-s-patent-expanding-acoustic-sensing-and-fluid-monitoring-e0c78764) — Source: HeartBeam
- 2026-06-30 11:00 EST — BEAT — [HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule](https://biopharmsignal.com/news/BEAT/heartbeam-completes-enrollment-in-heart-attack-detection-pilot-study-ahead-of-sc-c3aedd75) — Source: HeartBeam
- 2026-06-24 20:05 EST — BEAT — [HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition](https://biopharmsignal.com/news/BEAT/heartbeam-announces-strategic-shift-to-accelerate-global-adoption-of-its-ambulat-2e1e9ad3) — Source: HeartBeam
- 2026-06-15 13:15 EST — INBX — [Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma](https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86) — Source: Inhibrx
- 2026-06-03 12:00 EST — CTMX — [CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer](https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer) — Source: CytomX Therapeutics, Inc.
- 2026-06-02 11:00 EST — BEAT — [HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home](https://biopharmsignal.com/news/BEAT/heartbeam-announces-new-peer-reviewed-article-demonstrating-potential-to-help-identify-heart-attack-risk-at-home) — Source: HeartBeam
- 2026-06-01 12:00 EST — IMTX — [Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-and-response-dynamics-of-anzu-cel-prame-cell-therapy-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-31 13:00 EST — IMTX — [Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer](https://biopharmsignal.com/news/IMTX/immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-development-of-ima401-ima402-combination-in-lung-cancer) — Source: Immatics
- 2026-05-30 12:00 EST — IMTX — [Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-27 13:00 EST — GDRX — [GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs](https://biopharmsignal.com/news/GDRX/goodrx-launches-goodrx-companion-a-new-subscription-designed-to-lower-everyday-healthcare-costs) — Source: GoodRx
- 2026-05-26 20:10 EST — MDRX — [Veradigm Files 2023 and 2024 Form 10-K](https://biopharmsignal.com/news/MDRX/veradigm-files-2023-and-2024-form-10-k) — Source: Veradigm
- 2026-05-26 12:01 EST — MDRX — [Veradigm to Release Business Update May 26th and Host Investor Call May 27th](https://biopharmsignal.com/news/MDRX/veradigm-to-release-business-update-may-26th-and-host-investor-call-may-27th) — Source: Veradigm
- 2026-05-22 17:15 EST — IMMX — [Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 12:00 EST — CTMX — [CytomX Therapeutics to Present at Upcoming June Investor Conferences](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences) — Source: CytomX Therapeutics, Inc.
- 2026-05-21 06:30 EST — IMMX — [Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 06:00 EST — IMMX — [Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relapsed-refractory-al-amyloidosis-clinical-trial-nexicart-2) — Source: Immix Biopharma
- 2026-05-18 12:00 EST — CTMX — [CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-mamata-gokhale-ph-d-rac-as-senior-vice-president-of-regulatory-affairs) — Source: CytomX Therapeutics, Inc.
- 2026-05-16 02:00 EST — MTLS — [Materialise houdt jaarlijkse aandeelhoudersvergadering op 16 juni 2026](https://biopharmsignal.com/news/MTLS/materialise-houdt-jaarlijkse-aandeelhoudersvergadering-op-16-juni-2026) — Source: Materialise
- 2026-05-15 20:01 EST — MTLS — [Materialise to Hold Annual Shareholders’ Meeting on June 16, 2026](https://biopharmsignal.com/news/MTLS/materialise-to-hold-annual-shareholders-meeting-on-june-16-2026) — Source: Materialise

## Companies

- [ME](https://biopharmsignal.com/company/ME) — 23andMe
- [ACCD](https://biopharmsignal.com/company/ACCD) — Accolade
- [AFMD](https://biopharmsignal.com/company/AFMD) — Affimed
- [AKLI](https://biopharmsignal.com/company/AKLI) — Akili
- [AMWL](https://biopharmsignal.com/company/AMWL) — American Well
- [AUGX](https://biopharmsignal.com/company/AUGX) — Augmedix
- [AXON](https://biopharmsignal.com/company/AXON) — Axon Enterprise, Inc.
- [BTTX](https://biopharmsignal.com/company/BTTX) — Better Therapeutics
- [BCYC](https://biopharmsignal.com/company/BCYC) — Bicycle Therapeutics
- [BTCY](https://biopharmsignal.com/company/BTCY) — Biotricity
- [BFLY](https://biopharmsignal.com/company/BFLY) — Butterfly Network
- [CERT](https://biopharmsignal.com/company/CERT) — Certara
- [CDTX](https://biopharmsignal.com/company/CDTX) — Cidara Therapeutics
- [CGEN](https://biopharmsignal.com/company/CGEN) — Compugen Ltd.
- [CTMX](https://biopharmsignal.com/company/CTMX) — CytomX Therapeutics, Inc.
- [DOCS](https://biopharmsignal.com/company/DOCS) — Doximity
- [EPAM](https://biopharmsignal.com/company/EPAM) — EPAM Systems
- [EXAI](https://biopharmsignal.com/company/EXAI) — Exscientia
- [FNCH](https://biopharmsignal.com/company/FNCH) — Finch Therapeutics
- [FORA](https://biopharmsignal.com/company/FORA) — Forian
- [GDRX](https://biopharmsignal.com/company/GDRX) — GoodRx
- [HCWB](https://biopharmsignal.com/company/HCWB) — HCW Biologics
- [HCAT](https://biopharmsignal.com/company/HCAT) — Health Catalyst
- [HSTM](https://biopharmsignal.com/company/HSTM) — HealthStream
- [BEAT](https://biopharmsignal.com/company/BEAT) — HeartBeam
- [HSCS](https://biopharmsignal.com/company/HSCS) — HeartSciences
- [HSIC](https://biopharmsignal.com/company/HSIC) — Henry Schein
- [HIMS](https://biopharmsignal.com/company/HIMS) — Hims & Hers
- [IMTX](https://biopharmsignal.com/company/IMTX) — Immatics
- [IMMX](https://biopharmsignal.com/company/IMMX) — Immix Biopharma
- [INBX](https://biopharmsignal.com/company/INBX) — Inhibrx
- [INM](https://biopharmsignal.com/company/INM) — InMed
- [TRNR](https://biopharmsignal.com/company/TRNR) — Interactive Strength
- [IQV](https://biopharmsignal.com/company/IQV) — IQVIA
- [JANX](https://biopharmsignal.com/company/JANX) — Janux
- [KYMR](https://biopharmsignal.com/company/KYMR) — Kymera
- [LVTX](https://biopharmsignal.com/company/LVTX) — LAVA Therapeutics N.V.
- [MGRX](https://biopharmsignal.com/company/MGRX) — MANGOCEUTICALS
- [MTLS](https://biopharmsignal.com/company/MTLS) — Materialise
- [MRSN](https://biopharmsignal.com/company/MRSN) — Mersana Therapeutics
- [MRUS](https://biopharmsignal.com/company/MRUS) — Merus
- [MODN](https://biopharmsignal.com/company/MODN) — Model N
- [NRC](https://biopharmsignal.com/company/NRC) — National Research Corporation
- [NMRD](https://biopharmsignal.com/company/NMRD) — Nemaura Medical
- [NEXI](https://biopharmsignal.com/company/NEXI) — NexImmune
- [NRIX](https://biopharmsignal.com/company/NRIX) — Nurix Therapeutics
- [OMCL](https://biopharmsignal.com/company/OMCL) — Omnicell
- [PASO](https://biopharmsignal.com/company/PASO) — Patient Access Solutions
- [RVTY](https://biopharmsignal.com/company/RVTY) — PerkinElmer
- [PYXS](https://biopharmsignal.com/company/PYXS) — Pyxis Oncology
- [RLAY](https://biopharmsignal.com/company/RLAY) — Relay Therapeutics
- [RMD](https://biopharmsignal.com/company/RMD) — ResMed
- [SDGR](https://biopharmsignal.com/company/SDGR) — Schrodinger
- [SHCR](https://biopharmsignal.com/company/SHCR) — Sharecare
- [SLP](https://biopharmsignal.com/company/SLP) — Simulations Plus
- [SOPH](https://biopharmsignal.com/company/SOPH) — Sophia Genetics
- [STRM](https://biopharmsignal.com/company/STRM) — Streamline Health
- [TDOC](https://biopharmsignal.com/company/TDOC) — Teladoc
- [VCNX](https://biopharmsignal.com/company/VCNX) — Vaccinex
- [VEEV](https://biopharmsignal.com/company/VEEV) — Veeva
- [MDRX](https://biopharmsignal.com/company/MDRX) — Veradigm
- [HOWL](https://biopharmsignal.com/company/HOWL) — Werewolf Therapeutics